月份: 2026 年 3 月

伊拉克墜毀的KC-135加油機6名機組人員全部罹難，美國死亡人數增至至少13名軍事人員

hk_news

(SeaPRwire) -   美國軍方週五表示，一架在支援對伊朗行動時墜毀的KC-135空中加油機上，六名機組人員全部罹難。 負責中東地區的美國中央司令部表示，週四在伊拉克西部發生的墜機事件，是在「友方空域」涉及兩架飛機的未指明事件之後發生的，另一架飛機已安全降落。 這起墜機事件使「史詩憤怒行動」中美國的死亡人數增至至少13名軍人，其中另外七人是在戰鬥中喪生的。五角大廈本週稍早表示，約有140名美國軍人受傷，其中八人傷勢嚴重。 KC-135已服役超過60年，曾涉及多起致命事故，最近一起發生在2013年。更令人擔憂其可靠性的是，這些飛機並非總是配備降落傘。 以下是截至目前關於這架加油機的已知資訊，這是自2月28日對伊朗戰爭開始以來，第四架被公開承認墜毀的美國軍用飛機： 墜機原因尚不清楚 美國中央司令部表示，墜機情況正在調查中，但飛機損失「並非由於敵方或友軍火力造成」。 一位不願透露姓名的美國官員在討論最新情況時表示，涉及的另一架飛機也是KC-135。美國以色列大使葉希爾·萊特納（Yechiel Leiter）在X平台上發文稱，另一架飛機已在以色列安全降落。 參謀長聯席會議主席丹·凱恩（Gen. Dan Caine）將軍週五上午在五角大廈告訴記者，墜機事件發生在「伊拉克西部友方領土上空，當時機組人員正在執行戰鬥任務」，並重申敵方或友軍火力並非原因。 在同一場新聞發布會上，國防部長皮特·赫格塞斯（Pete Hegseth）稱這些機組人員是英雄。 「戰爭就是地獄，戰爭就是混亂，」赫格塞斯說。「正如我們昨天看到我們的KC-135加油機悲慘墜毀一樣，壞事可能會發生。他們都是美國英雄。」 赫格塞斯和凱恩是在六名機組人員的死亡消息公開之前向記者發表談話的。 韓國峨山政策研究院安全專家楊旭（Yang Uk）表示，加油機被敵方火力擊落的情況很罕見，因為這類行動通常在戰區後方進行。 上週，三架美國F-15E戰鬥機被科威特友軍火力誤擊墜毀，六名機組人員均安全彈射逃生。 KC-135是長期服役的加油機 KC-135 Stratotanker是美國空軍用於在空中為其他飛機加油的飛機，使它們能夠飛行更遠的距離，並在無需降落的情況下維持更長時間的運作。據軍事專家表示，該飛機還用於在醫療撤離期間運送傷員或執行偵察任務。 「這些飛機的最後一批是在1960年代生產的，」楊旭說。 基於與Boeing 707客機相同的設計，KC-135隨著更多新一代KC-46A Pegasus加油機投入使用，它將逐步淘汰。 根據國會研究處的資料，空軍去年擁有376架KC-135，其中包括151架現役、163架在空軍國民警衛隊，以及62架在空軍預備役。 基本的KC-135機組人員由三人組成：一名飛行員、一名副駕駛和一名加油桿操作員。在航空醫療撤離任務中會增加護士和醫療技術人員。 加油通常在飛機後方進行，加油桿操作員就位於該處。燃油加油桿會降下以與戰鬥機、轟炸機或其他飛機連接。在許多飛機上，加油桿操作員以俯臥姿勢工作，同時透過飛機底部的窗戶向外觀看。 一些KC-135還可以從機翼上的吊艙為飛機加油。這些加油機在需要時有空間載運貨物或乘客。 楊旭表示，如果對伊朗的戰爭持續下去，加油機可能發揮越來越重要的作用，因為美國飛機可能需要執行更長時間的任務，以追擊撤退到該國更深處的伊朗部隊。 關於降落傘的問題 KC-135曾涉及多起致命事故。最近一起發生在2013年5月3日，當時一架飛機在支援阿富汗戰爭時，於吉爾吉斯斯坦查爾多瓦爾（Chaldovar）以南起飛後墜毀。 根據美國空軍的調查，在那次墜機事件中，機組人員遇到了飛機方向舵的問題。當機組人員努力穩定飛機時，機尾部分斷裂，飛機在空中爆炸，機上三人全部喪生。 涉及該飛機最嚴重的空中相撞事故發生在1966年，當時一架攜帶核彈的B-52轟炸機在西班牙帕洛馬雷斯（Palomares）附近撞上了一架加油機。 這起事故導致加油機墜毀，機上四人喪生。這場災難引發了大規模的淨化工作，以清理氫彈中的常規炸藥在撞擊地面後引爆而擴散的核物質。 曾調查涉及KC-135事故的前空軍安全中心調查員艾倫·迪爾（Alan Diehl）表示，該飛機整體安全記錄良好，維護得當，並經常更新新設備。 但迪爾表示，一個重要問題是這架KC-135是否攜帶了任何降落傘。根據調查，在吉爾吉斯斯坦墜毀的那架飛機並未配備。 迪爾表示，不總是要求配備降落傘的原因，至少在1980年代和1990年代，包括維護和訓練使用它們的費用。他說K-135的設計在駕駛艙設有逃生艙口和擾流板，以幫助飛行員跳離機身。 一份2008年來自空中加油單位的新聞稿表示，空軍正在從KC-135上撤除降落傘，並指出統計上待在飛機內更安全，「特別是在敵方領土上空飛行時」。 「從軍用飛機上移除降落傘聽起來可能很奇怪，但KC-135不像其他飛機，」新聞稿指出。「它們很少發生事故，KC-135機組人員需要使用降落傘的可能性極低。」 迪爾強調，目前尚不清楚降落傘是否能在伊拉克上空幫助機組人員。但他表示，第二架飛機安全降落顯示碰撞可能並非災難性的。 當被問及墜毀的飛機是否配備降落傘時，軍方僅表示事件原因仍在調查中。 至於為何墜毀的KC-135上有六人，迪爾表示，由於飛機可以在空中停留許多小時，其中一些人可能是備用機組人員。本文由第三方廠商內容提供者提供。SeaPRwire (https://www.seaprwire.com/)對此不作任何保證或陳述。 分類: 頭條新聞,日常新聞 SeaPRwire為公司和機構提供全球新聞稿發佈，覆蓋超過6,500個媒體庫、86,000名編輯和記者，以及350萬以上終端桌面和手機App。SeaPRwire支持英、日、德、韓、法、俄、印尼、馬來、越南、中文等多種語言新聞稿發佈。

Circle Internet (CRCL) 股票：2026 年 3 月分析師觀點

hk_news

TLDR Mizuho 將 Circle Internet Group (CRCL) 的目標價從 100 美元上調至 120 美元，並維持「中性」評級。 USDC 的交易量自 2018 年以來首次超越 Tether (USDT)，市場份額達到 64%，高於 30% 的歷史平均水平。 Bernstein 維持「優於大盤」評級，目標價為 190 美元，理由是穩定幣的採用率正在加速。 CRCL 股價年初至今上漲約 49%，在從 2 月份接近 50 美元的低點翻倍後，目前交易價格約在 114 至 118 美元之間。 USDC 的市值同比增長 72%，達到約 750 億至 780 億美元，目前已在 30 個區塊鏈網絡上運行。 (SeaPRwire) -   Circle Internet Group 一直是 2026 年初華爾街表現最亮眼的股票之一。該股年初至今上漲約 49%，表現優於持平的標普 500 指數和下跌的納斯達克 100 指數。這一漲勢吸引了分析師的關注，並引發了關於其未來漲幅空間的討論。 Circle Internet Group, CRCL Mizuho 週四將 CRCL 的目標價從 100 美元上調至 120 美元，同時維持「中性」評級。該機構指出，USDC 市場地位的顯著改善是此次上調的主要原因。 USDC 的交易量自 2018 年以來首次超過 Tether 的 USDT，佔據了 64% 的交易份額。相比之下，2019 年至 2025 年間的平均份額約為 30%。這是穩定幣市場的一個重大轉變。 Mizuho 還上調了其 2027 年的預測。該機構將有效錢包數量的預測從 1,000 萬個提高到 1,170 萬個，並將 USDC 市值預測從 1.23 億美元提高到 1.39 億美元。EBITDA 預測則從 9.22 億美元上調至 11.19 億美元。 該機構將 USDC 的活動趨勢和新興用例（包括 Polymarket 等預測市場和代理商務）歸功於推動前景改善的動力。 儘管如此，Mizuho 並非沒有顧慮。分析師指出，中期的低利率環境和日益激烈的競爭仍然是該股的隱憂。該機構表示，短期前景看起來不錯，但這些風險並未消失。 Bernstein 設定 190 美元目標價 Bernstein SocGen Group 的態度更為樂觀。該機構重申了「優於大盤」評級，並維持 190 美元的目標價。以 CRCL 約 118 美元的交易價格計算，這意味著較當前水平有約 60% 的上漲空間。 Bernstein 的觀點核心在於穩定幣的採用速度，特別是在 2025 年通過《GENIUS Act》之後，美國對穩定幣建立了聯邦監管框架，涵蓋了儲備金支持、披露和監督等內容。 這種監管透明度幫助 Circle 與傳統金融機構建立了信任。BlackRock 管理著 Circle Reserve Fund，BNY Mellon 擔任 USDC 儲備的主要託管人，且 Circle 已獲得 Fidelity 和 Goldman Sachs 的投資。 該股也與更廣泛的加密貨幣市場走勢脫鉤，後者自 2025 年底發生大規模槓桿清算事件以來一直承受壓力。CRCL 從 2 月初接近 50 美元的低點反彈，至今已翻了一倍多。 USDC 增長推動分析師評級上調 USDC 的市值同比增長 72%，達到約 750 億至 780 億美元。該穩定幣目前在 30 個區塊鏈網絡上運行，佔據了全球穩定幣市場約四分之一的份額。 並非所有分析師對估值的看法都一致。Needham 將其目標價從 190 美元下調至 130 美元，理由是預測利率下降，以及與更廣泛的加密貨幣回調相關的 USDC 供應增長阻力。H.C. Wainwright 維持 85 美元的「中性」評級，表示希望看到 USDC 市值的持續增長，並在重新評估前，需要聯準會對 2026 年利率路徑提供更明確的指引。 根據 InvestingPro 的數據顯示，近期有四位分析師上調了盈利預期。該公司預計今年將實現盈利，儘管目前的毛利率為 8.67%。 根據 InvestingPro 的數據，追蹤該股票的四位分析師在最近幾週上調了盈利預期。本文由第三方廠商內容提供者提供。SeaPRwire (https://www.seaprwire.com/)對此不作任何保證或陳述。 分類: 頭條新聞,日常新聞 SeaPRwire為公司和機構提供全球新聞稿發佈，覆蓋超過6,500個媒體庫、86,000名編輯和記者，以及350萬以上終端桌面和手機App。SeaPRwire支持英、日、德、韓、法、俄、印尼、馬來、越南、中文等多種語言新聞稿發佈。

Robinhood (HOOD) 股價因二月交易活動降溫而下跌 2%

hk_news

TLDR 在 3 月 12 日發布 2 月份平台數據後，Robinhood 股價在盤後交易中下跌約 2%。 股票交易額為 1,944 億美元，較 1 月下降 14%，但較去年同期增長 36%。 期權交易量亦較上月下滑，共交易 1.803 億份合約，較 1 月減少 10%。 加密貨幣交易表現亮眼，交易額達 250 億美元，較 1 月增長 9%，較去年同期增長 74%。 月底平台總資產為 3,140 億美元，較 1 月下降 3%，但較去年同期增長 68%。 (SeaPRwire) -   Robinhood 於 3 月 12 日報告了其 2 月份的營運數據，市場對此反應冷淡。由於數據顯示其核心交易類別表現參差不齊，該公司股價在盤後交易中下跌了約 2%。 Robinhood Markets, Inc., HOOD 該月股票交易額為 1,944 億美元。這比 1 月下降了 14%，但仍比去年 2 月高出 36%。平均每日股票交易額為 102 億美元，較上月下降 11%，但較去年同期增長 36%。 Robinhood 應用程式本身的表現則較為疲軟。應用程式層面的平均每日交易額較去年同期下降 35%，至 3.36 億美元，這與整個平台較強勁的表現形成對比。 期權交易同樣表現不佳。該平台 2 月份處理了 1.803 億份期權合約，較 1 月下降 10%。平均每日期權交易量為 950 萬份合約，較上月下降 5%，但較去年同期增長 9%。 事件合約（Event contracts）受到的打擊最大。交易量較 1 月下降 29%，至 24 億份合約，平均每日交易量較上月下降 22%，至 8,600 萬份合約。 加密貨幣交易彌補缺口 加密貨幣是唯一實現增長的類別。Robinhood 報告 2 月份加密貨幣交易額為 250 億美元，較 1 月增長 9%，較一年前大幅增長 74%。儘管比特幣在月初經歷了劇烈拋售，但其持續的強勢表現有助於維持交易量處於高位。 其中，Robinhood 應用程式貢獻了 94 億美元的加密貨幣交易額，較 1 月增長 8%。不過，應用程式層面的加密貨幣平均每日交易額（ADV）仍比一年前低 35%。 截至 2 月底，現金和存款餘額為 165 億美元，較去年同期增長 67%。2 月份，Robinhood 更新了其經紀業務的高收益現金計劃（High-Yield Cash program）以支持保證金借貸的增長。此舉將超過 60 億美元的現金掃描（Cash Sweep）餘額轉移至自由信貸餘額中。 用戶增長保持穩定 客戶數量持續攀升。截至 2 月底，Robinhood 擁有 2,740 萬個注資帳戶，延續了穩定的上升趨勢。 月底平台總資產為 3,140 億美元，較 2026 年 1 月下降 3%，但較 2025 年 2 月增長 68%。月度環比下降反映了該期間交易活動放緩以及更廣泛的市場狀況。 華爾街對該股總體保持樂觀。分析師目前對 HOOD 的共識評級為「強力買入」，基於過去三個月的 14 個買入評級、2 個持有評級和 0 個賣出評級。平均目標價為 125.77 美元。本文由第三方廠商內容提供者提供。SeaPRwire (https://www.seaprwire.com/)對此不作任何保證或陳述。 分類: 頭條新聞,日常新聞 SeaPRwire為公司和機構提供全球新聞稿發佈，覆蓋超過6,500個媒體庫、86,000名編輯和記者，以及350萬以上終端桌面和手機App。SeaPRwire支持英、日、德、韓、法、俄、印尼、馬來、越南、中文等多種語言新聞稿發佈。

AdsDrama Launches Short-Drama Marketing Ecosystem Launch in the Dominican Republic, Paving the Way for Digital Content Innovation

acn

Santo Domingo, Dominican Republic, Mar 14, 2026 - (ACN Newswire via SeaPRwire.com) - In a strategic move to tap into the booming global short-drama market, AdsDrama LTD, an international digital content marketing company registered in Denver with $50 million in capital, has officially launched its tailored short-drama marketing ecosystem in the Dominican Republic. This event marks the company’s key step in expanding its global footprint, aiming to bridge the local content supply gap and build a sustainable digital entertainment model that combines its core strengths in advertising technology and community-driven growth.Short dramas — dozens of 1–3 minute episodes with fast-paced, emotional storytelling—are booming globally, fitting today's fragmented viewing habits. AdsDrama LTD, an international digital content marketing firm, is building a short-drama marketing ecosystem in the Dominican Republic, combining ad technology and community-driven strategies for sustainability.Short Dramas: The Next Digital Entertainment Growth EngineGlobal entertainment has shifted from long-form to short-form content, with short dramas offering advantages: 1–3 minute episodes, engaging storylines, mobile optimization, and higher monetization. The "free viewing + paid unlocking" model effectively retains audiences and generates revenue, fostering a full ecosystem of production, marketing, and commercialization.AdsDrama: Focused on Short-Drama MarketingRegistered in Denver with $50 million capital, AdsDrama's mission is a global short-drama marketing ecosystem integrating ad technology, distribution, data-driven strategies, and community promotion. Its core businesses include short-drama marketing, ad services, commercial operations, custom production, and IP incubation. Operating via "global technology + local operations," it adapts global expertise to local markets.Digital Advertising: The Growth EngineEffective distribution is key for short dramas. AdsDrama promotes content across social media, short-video platforms, portals, and search channels, optimizing campaigns via data analytics. Revenue streams include advertising, paid content, brand partnerships, and IP commercialization—forming the industry's financial foundation.Community-Driven "Co-Builder" ModelAdsDrama's "co-builder ecosystem" invites local participants to share content, provide market feedback, and expand reach. In return, co-builders get marketing materials, data access, and training—leveraging community trust, which outweighs algorithmic traffic in Latin America.User Experience & VIP StructureNew users get a free trial (RD$25–RD$60) to learn the platform's workflow and revenue model. For deep engagement, VIP levels (e.g., VIP3: RD$16,200 participation, daily returns of RD$270–RD$648 for 730 days) offer tiered benefits, with automatic revenue calculation and principal return options post-cooperation.Why the Dominican Republic?The country is a key market due to its young population (high digital entertainment demand), widespread mobile internet usage, and a gap in professionally produced short dramas—creating ideal conditions for ecosystem development.Three-Phase Development StrategyAdsDrama's 3-year plan: Phase 1 (1–6 months): Launch flagship dramas, build user communities, optimize marketing; Phase 2 (7–18 months): Expand promotion, improve operations, diversify revenue; Phase 3 (19–36 months): Open to independent creators, build a comprehensive ecosystem, and expand to the Caribbean and Latin America.The Future of the Digital Content EcosystemAs mobile internet continues to evolve, the digital entertainment industry is undergoing constant transformation.Short videos changed how audiences consume media. Short dramas may represent the next stage of this evolution - combining storytelling, advertising, and digital commerce in a single content format.Companies like AdsDrama LTD believe that the future of digital content will rely on the integration of multiple elements:creative storytellingtechnology infrastructuredata-driven marketingcommunity-based promotionIn this ecosystem:creators focus on producing contentplatforms provide technology and marketing toolscommunities help amplify distributionTogether, these elements form a sustainable and scalable digital content economy.Short dramas represent the next evolution of digital entertainment, integrating storytelling, advertising, and commerce. AdsDrama's focus on infrastructure, community, and data will drive the industry's growth, with the Dominican Republic and Latin America at the forefront of this transformation.Media contactBrand: AdsDrama LTDContact: Media teamWebsite: https://www.adsdrama.com Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

前總統候選人 Andrew Yang 表示，現在是時候「停止對勞動力徵稅」，改為向 AI 徵稅以填補財政缺口

hk_news

(SeaPRwire) -   2025年，個人所得稅佔美國政府總稅收的一半以上，總額達2.6兆美元，是政府收入中佔比最大的一部分。然而，所得稅並非一直以來都是稅收的核心。事實上，在美國建國約100年後，直到亞伯拉罕·林肯總統為資助內戰而簽署了第一項聯邦所得稅法（對超過800美元的收入徵收3%的單一稅率）時，所得稅的概念才被引入。正如所得稅並非自古就有，它也未必會永遠存在。 如果前總統候選人兼 Noble Mobile 執行長 Andrew Yang 的想法得以實現，情況可能會改變。在接受 CNBC’s Squawk Box 採訪時，Yang 表示，美國現在是時候放棄對勞動力徵稅，轉而對 AI 徵稅了。他主張，稅收是一種用來抑制特定行為的工具，而在人類就業受到威脅的情況下，政府不應再懲罰企業僱用人員的行為。 「我們將處於一個需要在每個季度、每個組織和環境中鞏固勞動力的位置，」他說。「我們實際上應該試著停止對勞動力徵稅」，轉而開始對 AI 徵稅。 Yang 並非第一個提出放棄對勞動力徵稅想法的人。這項議題已引起億萬富翁和政治人物的關注。參議員 Cory Booker (D-NJ) 最近提出一項法案，旨在免除前75,000美元收入的所得稅。Khosla Ventures 創辦人兼億萬富翁 Vinod Khosla 在最近接受 總編輯 Alyson Shontell 採訪時表示，總統候選人應將「取消年收入低於100,000美元者的所得稅」作為競選政見。 然而，根據智庫 Bipartisan Policy Center 的數據，去年年收入在100,000美元或以下的人群僅貢獻了總所得稅收入的約15%。商業領袖和 AI 創業者預測，AI 很快將接管白領階級的許多工作，可能使失業率上升至20%（根據 Anthropic 執行長 Dario Amodei 的說法）。Microsoft AI 負責人 Mustafa Suleyman 認為，大多數白領工作可能在18個月內被取代。Yang 最近也做出了類似的預測，他的警告來自於他對 AI 行業的觀察。 「我剛從西部的一個 AI 會議回來，天哪！」他在同意主持人關於將稅收轉向 AI 的立場後說道。「他們告訴我，我們在未來六個月內將看到的變化，將超過過去十年所見的總和，因為變化的速度正呈指數級增長。」 儘管勞動力市場近幾個月表現出韌性，但已出現動搖跡象，上個月失業率升至4.4%，雇主裁員人數達91,000人。幾家大型科技公司已將大規模裁員歸咎於 AI。Jack Dorsey 的 Block 上個月裁減了近一半的員工，理由是 AI 帶來的生產力提升。本週早些時候，澳美科技公司 Atlassian 裁減了其全球10%的員工。（儘管 OpenAI 的 Sam Altman 警告稱，一些公司存在「AI 洗白」現象，即將裁員歸咎於 AI，但實際上是由於其他原因）。 超越 AI 時代：人形機器人的稅收制度 儘管 Yang 考慮將稅收體系從勞工轉向 AI 公司，但一些科技領袖認為對 AI 徵稅不可行。然而，有些人認為勞動力威脅並非來自聊天機器人，而是來自機器人，並主張美國應計劃對人形機器人所能執行的勞動進行徵稅。 AI 技術公司 AskHumans 創辦人 Zak Kidd 提議徵收「任務稅」，即企業每讓一個人形機器人執行取代人類員工的特定活動，就需繳納一筆費用。據 Kidd 表示，AskHumans 已被 The World Bank、Fidelity 和 The Ned 使用，他目前正積極向全國各地的州長推銷他的任務稅構想。這種「任務稅」模式旨在取代當雇主決定用機械系統取代人類員工時，政府所損失的稅收收入。 「我們想要做的是，對每一項由機器人執行的活動徵稅，並將其回饋給州政府，以填補財政缺口，」Kidd 在提到機器人未來可能取代人類勞動的任務時告訴 。 Kidd 以 Marriott 等飯店為例說明他的提案，指出將每小時28美元的人類管家替換為每小時2美元的機器人，會導致稅收大幅流失。即使對企業徵收少量稅款，所產生的成本總額仍低於人類員工。 與 Yang 不同，Kidd 認為對 AI 徵稅會引發太多邏輯問題，因為隨著越來越多公司將 AI 整合到工作流程中，很難界定 AI 在哪裡停止、人類的詮釋從哪裡開始。他認為，雖然 AI 威脅到白領工作，但機器人可能會取代體力勞動。 「我將 AI 視為知識工作的增強，」他說。「但我將機器人技術，特別是人形機器人技術，視為體力工作的替代品。」本文由第三方廠商內容提供者提供。SeaPRwire (https://www.seaprwire.com/)對此不作任何保證或陳述。 分類: 頭條新聞,日常新聞 SeaPRwire為公司和機構提供全球新聞稿發佈，覆蓋超過6,500個媒體庫、86,000名編輯和記者，以及350萬以上終端桌面和手機App。SeaPRwire支持英、日、德、韓、法、俄、印尼、馬來、越南、中文等多種語言新聞稿發佈。

BlackRock的拉里·芬克預測AI領域將出現破產：「這就是資本主義」

hk_news

(SeaPRwire) -   BlackRock執行長Larry Fink並不擔心人工智慧（AI）領域一些最大業者可能破產的可能性。事實上，他正期待這種情況發生。 在本週BlackRock 2026年基礎設施峰會的小組討論中，這家全球最大資產管理公司的執行長明確表示，隨著AI改變經濟，至少「一兩家」業者破產是不可避免的。 「這就是資本主義。我們會有一些巨大的成功，也會有幾次失敗。沒關係，我對此沒有意見。」Fink表示。 但這並不意味著他希望大型科技公司停止其高額的AI基礎設施投資。相反地，他希望有更多投資，他表示這對美國在AI競賽中擊敗中國尤為重要。 「他們可能在短期內過度投資，但長期需求會趕上來。」Fink說。 一位未具名超大型企業的執行長告訴Fink，即使最終證實他們過度投資，他們也樂於繼續投入。「我可以確定地告訴你一件事，我不能當第三名，」Fink說這位執行長告訴他。 BlackRock執行長的言論發表之際，根據投資銀行諮詢公司Evercore ISI的預測，Microsoft、Alphabet、Amazon和Meta等超大型企業未來12個月的資本支出將達到6500億美元。這比他們2025年投資的3800億美元增長了近70%。一些分析指出，未來三到五年內，這種支出可能達到數兆美元。 對Fink而言，這種競爭和投資是美國經濟運作方式的基礎。 「這就是資本主義的美妙之處，天啊，我們有五家、六家超大型企業，還有新進入者互相競爭，試圖擁有最好的模式。這就是資本主義的最佳狀態。」他說。 BlackRock並未立即回應的評論請求。 然而，Evercore在上個月的一份報告中指出，對AI的大量支出正使一些大型科技公司面臨現金流為負的風險，因為支出超過了收入。儘管這並不意味著公司無利可圖，但Evercore表示這對其股票估值來說是一個「紅旗」。 Evercore指出，目前這些科技公司的企業債務水平低於標準普爾500指數（S&P 500）公司的中位數，但由於資本支出增加，這些水平也在上升。 根據美國銀行（Bank of America）分析師Yuri Seliger的數據，Amazon、Alphabet、Meta、Microsoft和Oracle在2025年發行了1210億美元的公司債券，遠高於這些公司過去五年平均280億美元的水平。 據報導，Oracle在這群企業中特別突出，去年發行了260億美元的債務，計劃今年發行450億至500億美元之間。值得注意的是，Oracle在最近的季度業績中報告整體收入同比增長22%，這得益於與AI密切相關的雲基礎設施收入激增。 這有助於緩解人們對債務驅動的支出最終能否回本的擔憂。就Fink而言，他並不擔心。 「他們的股本回報率仍然比我的好，而我的股本回報率已經相當不錯了，」他笑著說。本文由第三方廠商內容提供者提供。SeaPRwire (https://www.seaprwire.com/)對此不作任何保證或陳述。 分類: 頭條新聞,日常新聞 SeaPRwire為公司和機構提供全球新聞稿發佈，覆蓋超過6,500個媒體庫、86,000名編輯和記者，以及350萬以上終端桌面和手機App。SeaPRwire支持英、日、德、韓、法、俄、印尼、馬來、越南、中文等多種語言新聞稿發佈。

杜拜旗艦加密貨幣會議Token2049在突然逆轉下因伊朗戰爭取消

hk_news

(SeaPRwire) -   根據一份聲明，原訂於四月下旬舉行的浮華加密貨幣會議Token2049 Dubai在週五上午宣布，由於中東戰爭，該會議將延至2027年才舉行。3月6日，儘管該地區的衝突已升級一周，主辦單位仍告訴活動將按計劃進行。 聲明指出，該會議做出此決定是因為「該地區持續的不確定性及其對安全、國際旅行和物流的影響」。 Token2049並非該地區暴力事件中首個取消的活動。其他幾個活動也被取消，包括在杜拜和阿布達比舉行的名為Megacampus Summit的創業與創新會議。體育活動也被取消，最顯著的例子是網球明星Daniil Medvedev在一場比賽後被困在杜拜。 2月28日美國和以色列襲擊伊朗後，暴力事件蔓延至中東其他地區。一場疑似空襲部分損壞了杜拜的主要機場，導彈碎片墜落在杜拜的豪華酒店島嶼Palm Jumeirah，造成四人受傷。 根據《華爾街日報》的報導，當Token2049主辦單位在週日告訴其持票人Telegram群組活動將按計劃進行時，有人在聊天中回應：「你們在說什麼？伊朗仍在攻擊杜拜機場。」 2025年，超過15,000人參加了該會議，主辦單位稱之為「節慶般的環境」。今年會議預定的主要演講嘉賓包括Eric Trump、Polymarket執行長Shayne Coplan以及Tether執行長Paolo Ardoino。本文由第三方廠商內容提供者提供。SeaPRwire (https://www.seaprwire.com/)對此不作任何保證或陳述。 分類: 頭條新聞,日常新聞 SeaPRwire為公司和機構提供全球新聞稿發佈，覆蓋超過6,500個媒體庫、86,000名編輯和記者，以及350萬以上終端桌面和手機App。SeaPRwire支持英、日、德、韓、法、俄、印尼、馬來、越南、中文等多種語言新聞稿發佈。

認識 Chresten Wilson，即將成為 United 史上資歷最深女性飛行員的機長——這份工作年薪 40 萬美元且無需大學學位

hk_news

(SeaPRwire) -   United Airlines 即將創造航空歷史。在該航空公司慶祝成立 100 週年之際，資深 Boeing 787 機長 Chresten Wilson 將成為 United 18,000 名飛行員中資歷最深的飛行員——也是第一位擔任此職位的女性。 她的崛起是 42 年職業生涯的巔峰，這段生涯中她在仍由男性主導的駕駛艙裡打破了常規（女性僅佔飛行員的 6%），而她的故事發表之際，正值航空公司面臨嚴重的飛行員短缺以及對新兵激增的需求。 「我做到了沒有其他女性完成的事情，」這位 64 歲的老人在剛從澳洲旅行回來後告訴 。「這證明了這是可以做到的，而且[我]正試圖激勵更多女性進入這個領域。」 除了聲望和環遊世界的生活方式外，擔任飛行員還帶來六位數字的薪水，不受 AI 影響，並且——或許令人驚訝的是——不需要大學學位。 航空公司飛行員需求量大——薪資可超過 400,000 美元 航空業是該國薪酬最高的領域之一。根據美國勞工統計局的數據，航空公司飛行員、副駕駛和飛行工程師的中位數基本薪資為 226,000 美元——比所有職業的全國中位數高出約 358%。 資歷和機型將薪資上限推得更高：根據 Business Insider 的說法，駕駛廣體國際航線飛機的機長每年可以賺到超過 400,000 美元。「這相當有利可圖，」Wilson 說。 對於有志成為飛行員的人來說，時機也非常有利。Boeing 預計，受航空旅行需求增長和退休潮的推動，未來二十年全球將需要約 660,000 名新飛行員。 這也是一個人工智慧在短期內不太可能取代的職業——使其成為尋求穩定、高薪職業的年輕工人的吸引人的選擇。  雖然這份工作需要廣泛的培訓，但不一定需要四年制學位。許多飛行員從飛行課程開始，努力獲得學生飛行員證書，然後是私人飛行員執照，逐步積累飛行小時數和額外證書。許多航空公司和航空學校運營專門的培訓學院，旨在將畢業生輸送到航空公司駕駛艙。 Wilson 成為 United 資深飛行員的旅程始於小學 對於 Wilson 來說，這是 9 歲時開始的夢想的實現。 「我笑得合不攏嘴。我從來沒有坐過飛機，」Wilson 告訴 ，回憶起她父親帶她去拍攝航空照片的那一天。當他問她為什麼這麼高興時，她回答得很乾脆：「這就是我長大後要做的事。」 她從未放棄過。幾年後，在與母親和姐姐搬到丹佛後，她開車經過 United 的培訓中心：「從來沒有人告訴我沒有女性航空公司飛行員……我只是把這件事記在心裡，這就是我要做的。」 年輕的 Chresten Wilson // Courtesy of United Airlines 她在丹佛上了大學，在那裡她開始了正規的飛行訓練，同時還在學校上學。在獲得證書後，她成為了一名飛行教官，並獲得了一個機會，因為她的一個學生恰好在 United 的培訓中心工作。這個學生給她帶來了一份申請表，但 Wilson 並不樂觀，認為不會有什麼結果。 「我認為我被錄用的機會微乎其微，因為那時候飛行員多如牛毛，但我猜我達到了他們的標準，並在 22 歲時被錄用了。」 她從飛行工程師——一個現已廢除的領航員職位——一路晉升為 Boeing 737 的副駕駛，最終成為機長。她擔任這個職位已經 31 年了。如今，她駕駛 787 從舊金山起飛，每月在空中飛行約 12 天，主要飛往澳洲和紐西蘭等地的長途國際航線。隨著另外兩名飛行員今年晚春時退休，她將成為資歷排名第一的飛行員。 儘管是一份高薪職業，但成為飛行員需要毅力——以及犧牲 Wilson 說，通往駕駛艙的道路幾乎比任何事情都更需要一致性。 「一旦你開始培訓，你就需要專注並保持一致。這不是你想開始就開始、想停止就停止的事情，」她補充道，有志成為飛行員的人不應被懷疑者嚇倒。「我不明白為什麼沒人能做到這一點。」 這份工作有真正的取捨。飛行員必須接受不斷的再培訓和定期熟練度檢查，而且旅行時間表可能很苛刻——尤其是在職業生涯早期，資歷較低的時候。 「你會經常不在家。當你資歷不夠深時，你往往會錯過孩子的生日和 T-ball 比賽，」Wilson 說。「……如果你想在每個聖誕節都待在家裡，這可能無法實現。」 「這並不適合所有人，」她補充道。「如果這是你真正想做的事情，資歷就是一切，所以堅持下去。不要害怕儘早開始向航空公司申請……如果這是你想做的事，就要堅持不懈。」 但對於那些願意承諾的人來說，她說，這是值得的。 「我總是[對我的機組人員]說，『別讓我上 CNN，別讓我成為下一次培訓活動中他們談論的人』，」Wilson 說。「『讓我們進行安全運作；我們想引來的唯一關注就是安全運作和順利著陸。』」本文由第三方廠商內容提供者提供。SeaPRwire (https://www.seaprwire.com/)對此不作任何保證或陳述。 分類: 頭條新聞,日常新聞 SeaPRwire為公司和機構提供全球新聞稿發佈，覆蓋超過6,500個媒體庫、86,000名編輯和記者，以及350萬以上終端桌面和手機App。SeaPRwire支持英、日、德、韓、法、俄、印尼、馬來、越南、中文等多種語言新聞稿發佈。

華通金融攜手清華大學共建AI與金融科技聯合實驗室

admin

EQS 新聞 / 2026-03-12 / 20:30 UTC+8 3月11日，於納斯達克掛牌的金融科技公司華通金融宣佈，與清華大學交叉資訊研究院關聯企業 X-Tech 以及 AI 技術公司 PandaAI 達成合作。三方將共同成立“AI與金融科技聯合實驗室”，探索 AI Agents在真實交易場景中的應用。 從“工具”到“夥伴”：AI如何重新定義金融決策 傳統的AI應用多為“輔助型工具”——它們可以回答問題、提供數據、生成報告，但最終的決策和執行仍需由人類完成。AI Agents引領的是一次質的飛越：它的形態不再局限於被動回應指令的程式，而是具備目標理解、自主規劃、動態執行與任務閉環能力的“智能體”。 在金融場景中，自主執行交易的AI Agents不僅會看K線、懂財報和讀新聞，更要理解宏觀經濟、市場情緒、資金流向，甚至地緣政治等因素與金融市場的相關性。它被期待成為經驗豐富的交易員，在瞬息萬變的市場中獨立完成從分析、研究，判斷到執行的完整閉環。 而華通金融此次與清華的合作將致力於讓AI Agents具備多維度分析能力和自主執行交易能力，包括：即時解析宏觀經濟數據與政策動向；融合新聞情緒與社交媒體輿情；對數千只股票進行基本面與技術面掃描；自動生成交易策略並進行回測驗證。最終，AI Agents不僅能向用戶解釋決策依據，還能執行交易指令。 聯合實驗室將由清華大學交叉資訊研究院的李建教授親自掛帥。作為AI交易領域的頂尖學者，李建團隊將提供前沿的演算法研究支持；PandaAI則貢獻基於量子理念啟發的新型AI方法；而華通金融將開放其安全的交易系統和真實的金融運營場景，為自主執行交易的AI Agents的訓練與驗證提供關鍵數據和落地通道，作為納斯達克上市公司, 其交易系統已經過多項安全驗證。 AI技術推動投資工具普及：當量化交易不再局限於機構 長期以來，量化交易與AI投資策略是機構投資者的“專利”。他們擁有龐大的研究團隊、昂貴的數據和稀缺的算力資源，能夠通過模型捕捉市場波動中的潛在機會。而個人投資者往往只能依賴碎片化的資訊和有限的分析工具，在這場“演算法戰爭”中處於劣勢。 華通金融旨在利用自主執行交易的AI Agents打破這一格局。這些具備自主交易能力的AI Agents有希望幫助用戶在無編程或量化知識背景的前提下，亦可以用自然語言完成投資指令下達，而此後的宏觀分析、行業比較、個股篩選，並執行交易等關鍵環節均由AI Agents自主完成。這項研究的意義在於令個人投資者有機會擁有接近機構級別的投研能力和量化交易團隊。此外聯合實驗室還將重點研究AI Agents在即時風控、合規檢查中的應用，確保智能交易系統在複雜市場環境下具備安全性和穩定性。 華通金融董事會主席周凱表示：“此次合作是增強我們的技術能力，並幫助個人與專業投資者把握AI驅動金融這一快速發展的領域，讓AI Agents真正理解市場運行的深層邏輯，幫助全球用戶做出更明智、更及時、更安全的決策。” 未來圖景：每個人都擁有自己的“量化交易員” 全球資本市場正經曆一場深刻的範式轉移。曾經，資訊與技術的壁壘將大多數人擋在門外；而今天，自主執行交易的AI Agents正在將“智能金融”的鑰匙交到每一個人手中。 全球資本市場正迎來技術普惠的新階段，AI正將專業投資工具帶入更多普通人的視野。試想，用戶只需對AI Agents說“我想配置一些低波動的科技股，預算2萬美元，持有6個月”，AI Agents即可自動篩選符合條件的標的、評估當前估值水準、生成投資組合建議，並在用戶授權後交易，且持續監控組合風險。 華通金融此次攜手清華打造可自主執行交易的AI Agents，不僅是尋求技術突破，更是在宣示：金融的未來，不應只是機構的專屬遊戲。當AI Agents走出高牆、當智能交易融入日常，每一位普通人都將有機會，以前所未有的方式理解並參與這個時代最複雜的市場。 提示：任何投資均存在風險，AI模型並不保證絕對盈利 2026-03-12 此財經新聞稿由EQS Group轉載。本公告內容由發行人全權負責。瀏覽原文: http://www.todayir.com/tc/index.php

General MRO Aerospace Achieves CAAC Certification, Expanding Global Maintenance Capabilities

acn

MIAMI, FL, Mar 13, 2026 - (ACN Newswire via SeaPRwire.com) - General MRO Aerospace (GMA) today announced that it has officially received certification from the Civil Aviation Administration of China (CAAC), authorizing the company to perform maintenance, repair, and overhaul (MRO) services for components on Chinese-registered aircraft.The certification marks a significant milestone in General MRO Aerospace's international growth strategy and further validates the company's commitment to the highest standards of safety, quality, and regulatory compliance."Achieving CAAC certification is an important step forward for General MRO Aerospace as we continue to expand our global footprint," said Jonathan Cornell, President of General MRO Aerospace. "This approval demonstrates the strength of our quality systems, our technical expertise, and our commitment to supporting Airline and MRO partners worldwide."The CAAC approval allows GMA to provide repair and overhaul services for a range of aircraft components in accordance with Chinese aviation regulatory requirements. The certification process included a comprehensive audit of the company's facilities, quality management system, technical procedures, and regulatory compliance programs.General MRO Aerospace already operates under FAA Part 145, EASA, CAA, and CAAT quality standards, and the addition of CAAC certification enables the company to better serve operators, lessors, and maintenance providers across the Asia-Pacific aviation market."With increasing global demand for high-quality component repair services, this certification strengthens our ability to support customers operating in China and throughout the region," Cornell added. "We look forward to building strong partnerships with Chinese airlines and aviation organizations."General MRO Aerospace specializes in the repair and overhaul of complex aircraft components, supporting commercial and cargo operators worldwide with reliable turnaround times, technical excellence, and customer-focused service.About General MRO AerospaceGeneral MRO Aerospace is an AS9110 and ISO 9001 accredited U.S.-based aviation maintenance, repair, and overhaul provider specializing in component repair and support services for commercial aircraft operators worldwide. Operating under FAA Part 145, EASA, CAA, CAAT, and CAAC certification, the company delivers high-quality technical solutions, responsive customer service, and dependable turnaround times to airlines, leasing companies, and MRO partners around the globe.Media ContactMichelle TorresMarketing SpecialistGeneral MRO AerospaceMtorres@GeneralMROAerospace.comwww.GeneralMROAerospace.comSOURCE: General MRO Aerospace Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

General MRO Aerospace 取得中國民航局認證，拓展全球維修能力

acn

佛羅里達州邁阿密, 2026年3月13日 - (亞太商訊 via SeaPRwire.com) - General MRO Aerospace（GMA）今日宣布，已正式獲得中國民用航空局（CAAC）的認證，授權該公司為中國註冊飛機的部件提供維修、保養及大修（MRO）服務。此項認證標誌著 General MRO Aerospace 國際發展戰略的重要里程碑，並進一步印證了該公司對最高安全標準、品質及法規遵循的承諾。「取得 CAAC 認證是 General MRO Aerospace 持續拓展全球業務版圖的重要一步，」General MRO Aerospace 總裁 Jonathan Cornell 表示。「這項批准彰顯了我們品質體系的實力、技術專長，以及對支持全球航空公司與 MRO 合作夥伴的承諾。」獲得民航局（CAAC）批准後，GMA 得以依照中國航空監管要求，為各類飛機組件提供維修與大修服務。認證過程包含對該公司設施、品質管理系統、技術程序及法規遵循計畫的全面審核。General MRO Aerospace 目前已遵循 FAA Part 145、EASA、CAA 及 CAAT 品質標準營運，此次新增的 CAAC 認證將使該公司能更完善地服務亞太航空市場中的營運商、租賃商及維修服務供應商。「隨著全球對高品質部件維修服務的需求日益增長，這項認證強化了我們支援在中國及整個地區營運客戶的能力，」康奈爾補充道。「我們期待與中國航空公司及航空組織建立堅實的合作夥伴關係。」General MRO Aerospace 專精於複雜飛機部件的維修與大修，憑藉可靠的週轉時間、卓越的技術實力及以客戶為中心的服務，為全球商用及貨運營運商提供支援。關於 General MRO AerospaceGeneral MRO Aerospace 是一家總部位於美國、通過 AS9110 及 ISO 9001 認證的航空維修、保養與大修服務供應商，專門為全球商用飛機營運商提供部件維修與支援服務。憑藉FAA Part 145、EASA、CAA、CAAT及CAAC認證，該公司為全球航空公司、租賃公司及MRO合作夥伴提供高品質的技術解決方案、反應迅速的客戶服務以及可靠的維修週期。媒體聯絡人Michelle Torres行銷專員General MRO AerospaceMtorres@GeneralMROAerospace.com www.GeneralMROAerospace.com 消息來源：General MRO Aerospace Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

CMS (867.HK/8A8.SG) : New Drug for Renal Anaemia Desidustat Tablets Approved in China

acn

SHENZHEN, CHINA, Mar 13, 2026 - (ACN Newswire via SeaPRwire.com) - China Medical System Holdings Limited (“CMS”, or the “Group”) is pleased to announce that on 13 March 2026, new drug for renal anaemia Desidustat Tablets (the “Product”) has been approved for marketing in China by the National Medical Products Administration of the People’s Republic of China (NMPA). The Product is a novel, oral HypoxiaInducible Factor-Prolyl Hydroxylase Inhibitor (HIF-PHI) for treating anaemia in non-dialysis adult, Chronic Kidney Disease (CKD) patients.The approval of Desidustat Tablets will further strengthen the Group’s overall layout in the field of nephrology, and synergize with the marketed innovative drug Velphoro (Sucroferric Oxyhydroxide Chewable Tablets, indicated for CKD hyperphosphatemia). Through the efficient linkage of nephrology expert resources and channel networks, the Group is expected to rapidly promote the large-scale clinical application of Desidustat Tablets, providing differentiated treatment options for Chinese CKD patients with renal anaemia and making a positive contribution to the Group’s performance.More information about Desidustat Tablets and Renal AnaemiaAs a novel oral HIF-PHI, the Product’s mechanism of action promotes erythropoiesis through increasing endogenous erythropoietin, improving iron availability and reducing hepcidin. Its China Phase III clinical trial has demonstrated positive results. The primary endpoint of the haemoglobin (Hb) mean change from baseline to Week 7-9 has indicated that, Desidustat is more effective than placebo in increasing Hb level. Results from the extension study demonstrate that the Product can maintain Hb level within the target range over the long term with acceptable safety. In addition, the Product significantly reduces hepcidin levels and ameliorates iron metabolism disorders.There is still a large unmet need in the treatment of anaemia in CKD patients in China. It is estimated that there are more than 120 million CKD patients in China[1]. Anaemia is one of the frequent complications of CKD, which exhibits a progressively increasing incidence with disease progression. A survey in China showed that the prevalences of anaemia in patients at CKD stage 1 to 5 were 22.0%, 37.0%, 45.4%, 85.1%, and 98.2%, respectively[2]. The target-achieving rate (the Hb level reaching the target value (110~120g / L)) has increased to 51.5% for haemodialysis CKD patients with anaemia[3], but is still only 8.2% for anaemia patients in non-dialysis CKD[4]. The Product is administrated orally, thus expecting to improve the treatment compliance of patients and to meet the unmet treatment needs in the field of CKD anaemia.Desidustat Tablets have been approved for marketing in India.CMS INTERNATIONAL DEVELOPMENT AND MANAGEMENT LIMITED, a wholly-owned subsidiary of the Group, obtained an exclusive license for the Product from Zydus Lifesciences Limited (earlier known as Cadila Healthcare Limited) pursuant to a License Agreement with an effective date of 20 January 2020.The Group adheres to its core strategy of “innovation-driven”, having established a tiered and multi-dimensional innovation product portfolio with abundant reserves: 7 new drugs have been approved for marketing, 6 are currently under marketing review, and nearly 20 projects are about to initiate or are progressing through clinical trials. Through a dual-engine innovation approach combining collaborative development and in-house R&D, the Group continuously enriches its innovative pipeline centered on first-in-class (FIC) and best-in-class (BIC) products, efficiently advancing clinical development and commercialization. Moving forward, CMS will remain clinical needs-driven to deliver more quality pharmaceutical solutions, steadfastly advancing toward the goal of becoming a specialty-focused, innovation-excellent multinational pharmaceutical enterprise.About CMSCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the Cardiovascular-Kidney-Metabolic/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group.Reference1. ZhangL, WangF, WangL, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey[J]. Lancet, 2012, 379(9818):815-822. DOI: 10.1016/S0140-6736(12)60033-62. Chinese Expert Consensus on the Diagnosis and Treatment of Renal Anemia (2014 Revised Edition)[J]. Chinese Journal of Nephrology, 2014, 30(9): 712-716. DOI: 10.3760/cma.j.issn.1001-7097.2014.09.0153. 19th CSN Critical Care & Blood Purification Congress, Chinese Medical Association (July 2-5, 2025)4. Chinese Expert Consensus on the Diagnosis and Treatment of Renal Anemia (2018 Revised Edition)[J]. Chinese Journal of Nephrology, 2018, 34(11): 860-866. DOI: 10.3760/cma.j.issn.1001-7097.2018.11.012CMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsWebsite: https://web.cms.net.cn/en/home/ Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

CMS (867.HK/8A8.SG): Ruxolitinib Phosphate Cream (Lumirix(R)) Achieves Initial Prescriptions in Multiple Regions in China for Patients with Vitiligo

seaprwire

SHENZHEN, CHINA, Mar 13, 2026 – (ACN Newswire via SeaPRwire.com) – On 12 March 2026, China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health, which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited) has its innovative prescription medicine ruxolitinib phosphate cream (Lumirix®) (the “Product”, marketed as Opzelura® in the U.S., Europe and Canada) recorded the initial prescriptions for vitiligo patients across 30 provincial-level regions. The prescriptions cover approximately a thousand influential public and private medical institutions in the field of skin health and disease management, including Huashan Hospital, Fudan University, Shanghai Skin Disease Hospital, Dermatology Hospital of Southern Medical University, Second People’s Hospital of Chengdu, The First Bethune Hospital of Jilin University, The Second Xiangya Hospital of Central South University, United Family Healthcare Group, among others*. Meanwhile, the Product has become concurrently accessible via over 1,300 offline drugstores as well as JD.com e-commerce platform. *Hospital rankings are listed in no particular order. As the first topical JAK inhibitor approved in China for the treatment of vitiligo, ruxolitinib phosphate cream has officially launched its large-scale clinical application today, marking a breakthrough in China’s vitiligo treatment landscape and ushering in a new era of precision targeted therapy for vitiligo. Supported by safety and efficacy fully demonstrated in clinical studies, the Product is expected to bring new hope for repigmentation to millions of vitiligo patients. The rapid commercialization progress of ruxolitinib phosphate cream underscores strong product operation capabilities of CMS (including Dermavon), while also reflecting the robust supports from China’s regulatory reforms in accelerating patient access to clinically urgently needed innovative drugs. Benefiting from the integrated healthcare ecosystem of the Hainan Free Trade Port and the “Urgently Needed Imported Drugs for Clinical Use” policy, the Product initiated pilot clinical use in August 2023 at Boao Super Hospital within the Boao Lecheng International Medical Tourism Pilot Zone. Pilot usage subsequently expanded to designated medical institutions across the Guangdong–Hong Kong–Macao Greater Bay Area, Beijing-Tianjin region and other regions. In accordance with the relevant regulations of China’s real-world data application pilot project, as well as supported by the Hainan Provincial Medical Products Administration and the Administration of the Boao Lecheng International Medical Tourism Pilot Zone, the Product has accumulated real-world clinical data in China under pilot application, significantly accelerating its clinical, registration and approval timelines. The Product received its Drug Registration Certificate on January 30, 2026 (approval date: January 27, 2026). Following its approval, in less than 1.5 months (including the Chinese New Year holiday), the initial prescriptions for ruxolitinib phosphate cream have been issued across multiple regions and hospitals, reflecting the highly efficient collaboration and concerted efforts among CMS teams, regulatory authorities and business partners. With robust support from the cross-departmental coordination mechanism of the Beijing Daxing Airport Economic Zone Joint Administrative Committee, once import conditions were met, the Product completed customs clearance approval, sampling and related customs procedures within 24 hours, and obtained the drug testing report within 7 working days, representing efficient execution and acceleration for the innovative drugs in China. During this process, the Beijing Municipal Medical Products Administration proactively provided end-to-end policy guidance; the government service center has efficiently completed customs clearance filing; the Beijing Institute for Drug Control has conducted methodological pre-testing to accelerate timelines for innovative drug, and continuous worked during the Chinese Spring Festival; and Daxing Airport Customs provided specialized pre-guidance on declaration and swiftly completed customs review and release. Through parallel workflows and coordinated execution, all parties collectively pressed the “fast-forward button” for the Product’s commercialization, helping this urgently needed innovative therapy reach patients faster. As the Product enters the large-scale clinical application stage, it is expected to further strengthen Dermavon’s comprehensive dermatology solutions and brand value. Building on its leadership in skin health, Dermavon will continue to improve accessibility of ruxolitinib phosphate cream to benefit more vitiligo patients and steadfastly safeguard public skin health through innovation. About Vitiligo Vitiligo is a chronic autoimmune disease characterized by depigmentation of the skin, which results from the loss of pigment-producing cells known as melanocytes. The discolored areas usually get bigger with time and the condition could influence skin on any part of the patients’ body. Vitiligo usually affects the appearance of patients, especially on exposed areas such as the face and neck. According to a study that involved over 1,000 diagnosed vitiligo patients, over 45% of patients have facial involvement, and over 20% of patients have neck involvement[1].The obvious presence of white patches may make patients feel that their appearance has been compromised, which in turn materially affects their social life, and is associated with a significantly higher incidence of mental health disorders; accordingly, there is an urgent need for effective treatment options for vitiligo[2]. It is estimated that there are approximately 10.3 million vitiligo patients in China and non-segmental vitiligo patients account for approximately 8.2 million[1]. Existing therapies, such as topical corticosteroids (TCS) and topical calcineurin inhibitors (TCIs), have clinical limitations, with adverse reactions or limited efficacy with long-term use. Ruxolitinib phosphate cream successfully fills the gap in targeted drug treatment for vitiligo and is of great landmark significance. More Information About Ruxolitinib Phosphate Cream Ruxolitinib phosphate cream (Opzelura®), a novel cream formulation of the selective JAK1/JAK2 inhibitor ruxolitinib developed by Incyte, is the first and only drug approved for the repigmentation of non-segmental vitiligo by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA)[3,4]. In the U.S., the Product is indicated for the topical treatment of nonsegmental vitiligo in adult and pediatric patients aged 12 years and older, and for the short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis (AD) in non-immunocompromised adult and pediatric patients aged 2 years and older whose disease is not well controlled with topical prescription therapies, or when those therapies are not advisable. In Europe, ruxolitinib phosphate cream is approved for the topical treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age. In China, besides vitiligo indication, the product’s NDA for the treatment of mild-to-moderate AD in adults and pediatric patients aged 2 years and older is also under regulatory review, which has been included in the Priority Review List and is expected to accelerate the Product’s AD review process for marketing approval. The Group, through the subsidiary of Dermavon entered into a Collaboration and License Agreement with Incyte for ruxolitinib phosphate cream on 2 December 2022, obtaining an exclusive license to develop, register and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in the Territory. The subsidiary of Dermavon has sublicensed the relevant rights for the Product outside of Mainland China to the Group (excluding Dermavon and its subsidiary). Incyte has worldwide rights for the development and commercialization of ruxolitinib phosphate cream (excluding territories in which exclusive rights have already been licensed), marketed in the United States and Europe as Opzelura®. Opzelura® and the Opzelura® logo are registered trademarks of Incyte. About CMS CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs. CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients. CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardiovascular-kidney-metabolic/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group. Reference: 1. China Insights Consultancy’s industrial report  2. Wang G, Qiu D, Yang H, Liu W. The prevalence and odds of depression in patients with vitiligo: a meta-analysis[J]. Journal of the European Academy of Dermatology and Venereology, 2018,32(8):1343-1351. DOI:10.1111/jdv.14739.  3. The U.S. FDA approval information can be found on the Incyte official website, as follows: https://investor.incyte.com/news-releases/news-release-details/incyte-announces-us-fda-approval-opzeluratm-ruxolitinib-cream 4. The EMA approval information can be found on the Incyte official website, as follows: https://investor.incyte.com/news-releases/news-release-details/incyte-announces-european-commission-approval-opzelurar CMS Disclaimer and Forward-Looking Statements This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert. This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.

伊朗戰爭如何切斷東南亞的旅遊業

hk_news

(SeaPRwire) -   伊朗戰爭正在重塑全球航線，對東南亞關鍵的旅遊業構成威脅。伊朗的飛彈與無人機攻擊已導致杜拜、阿布達比和杜哈等中東航空樞紐關閉，切斷了歐洲與美國旅客前往東南亞海灘與寺廟的熱門航線。旅遊專家現在擔心，泰國、柬埔寨和印尼等國的遊客數量可能很快就會下滑。 「歐洲與峇里島、柬埔寨等目的地之間並沒有直飛航班，」新加坡獨立航空分析師 Brendan Sobie 表示。「這些高度依賴旅遊業的國家，由於經濟上的連鎖反應，受到的衝擊也更大。」 旅遊業是東南亞經濟的支柱。2024 年，旅遊業佔柬埔寨 GDP 的 9.4%，佔泰國 GDP 的 12%。 包括 Emirates、Qatar Airways 和 Etihad 在內的主要海灣航空公司已取消了數千架往返中東的航班。這對部分東南亞航空公司產生了連鎖反應；例如，Malaysia Airlines 依賴 Qatar Airways 將來自美國、歐洲和中東的遊客轉運至東南亞。 「Malaysia Airlines 除了倫敦和巴黎外，飛往歐洲的航班並不多，」航空諮詢公司 OAG 的亞洲負責人 Mayur Patel 表示。「他們許多代碼共享航班都是透過 Qatar Airways 在杜哈轉機，如果飛機無法飛往杜哈，肯定會對交通流量造成限制。」 全球航空公司受到何種衝擊？ 全球航空網絡受到領空關閉和航空燃油價格飆升的衝擊，燃油價格自伊朗衝突開始以來已翻了一倍。航空公司正將部分中東航線暫停數週甚至數月。航空公司也開始對航班徵收燃油附加費，Air New Zealand 由於燃油成本增加，已於週二撤回了財務指引。 「在戰爭的第一週，我們看到總預訂量下降了 50%，」在杜拜、倫敦、新加坡和香港設有辦事處的豪華旅遊公司 Lightfoot Travel 的聯合創始人兼董事總經理 Lucy Jackson Walsh 表示。中東目的地的預訂量（約佔 Lightfoot 業務的 15%）幾乎瞬間消失。 「我們正在將重心轉向亞洲區域內的旅遊，以及前往澳洲等不需要經過中東航線的更遠目的地，」她說。 領空和航道關閉導致的供應鏈中斷也延誤了飛機維護、維修和大修（MRO）工作，並加劇了 Airbus 和 Boeing 等製造商現有的飛機交付延遲問題。 「航空航太零組件和零件出現短缺，這些零件可能來自歐洲或美國，」獨立航空航太顧問 Kent Yar 表示。「製造飛機零件也需要原材料……一切都歸結為供應鏈問題。」他估計，自伊朗戰爭開始以來，飛機備用零件的價格已上漲了 15%。 是否有航空公司能從中受益？ 儘管如此，一些經營亞洲與歐洲之間多條直飛航線的亞洲航空公司，如 Singapore Airlines 和香港的 Cathay Pacific，可能比其他受影響的航空公司更具優勢。「鑑於俄烏戰爭，亞洲與歐洲之間現有的直飛航班已經重新規劃航線，並不一定會使用伊朗或中東領空，」Sobie 解釋道。 但與該行業遭受的整體打擊相比，這只是微不足道的安慰。 「我不認為有任何人會感到高興，」Sobie 說。「有些航空公司的航線可能會看到載客率和收入的額外激增——這是自然的——但這無法抵銷這場危機對整個行業造成的負面影響。」 即便如此，業內仍有人希望衝突平息後情況能有所恢復。 「我希望在衝突平息後能看到報復性旅遊，」Lightfoot 的 Walsh 說。「就像 COVID-19 疫情之後，市場回暖，旅遊業再次起飛一樣。」本文由第三方廠商內容提供者提供。SeaPRwire (https://www.seaprwire.com/)對此不作任何保證或陳述。 分類: 頭條新聞,日常新聞 SeaPRwire為公司和機構提供全球新聞稿發佈，覆蓋超過6,500個媒體庫、86,000名編輯和記者，以及350萬以上終端桌面和手機App。SeaPRwire支持英、日、德、韓、法、俄、印尼、馬來、越南、中文等多種語言新聞稿發佈。

CITIC Resources Deepens Dual-Engine Strategy of ‘Investment + Trading’, Continues to Promote High-Quality Development

acn

HONG KONG, Mar 13, 2026 - (ACN Newswire via SeaPRwire.com) – CITIC Resources Holdings Limited (hereinafter referred to as CITIC Resources or the Company, or the Group when its subsidiaries are included; Stock Code: 1205.HK) has announced its annual results for the year ended 31 December 2025 (the “Year”). During the Year, the Group actively responded to the complex international environment and cyclical industry pressures. Systematically advancing initiatives in “upstream asset deployment, expansion of trading business, and enhancement of production and operations”, the Group deepened its dual-engine development model of “investment + trading”, stabilised its core operations, cultivated a second growth curve, and demonstrated robust operational and developmental resilience.As a key growth driver for the Group, the oil and gas trading business within the import and export segment expanded steadily during the Year, achieving a significant milestone with a trading volume exceeding 20.0 million barrels and revenue reaching approximately HK$11.34 billion. Meanwhile, the Group broke the long-standing monopoly of the sales channel of crude oil, enhancing the market value of its oil and gas properties. In the non-oil-and-gas business, the Group consistently prioritises refined and proactive management of its equity investments as a core task and actively conveyed its philosophy of improving quality and enhancing efficiency to the operators. Notably, the value of shares held in Aloca Corporation (“Aloca”) increased by approximately 46.3% during the Year. On the oil and gas front, focusing on refined reservoir management and continuous scientific research breakthroughs, the Group achieved stable production and increased reserves. It comprehensively deepened lean management throughout the production process, coupled with the implementation of cost-reduction and efficiency-enhancement measures, propelled continuous improvements in management standards and operational efficiency across all phases of oil and gas projects from exploration, development to production.During the Year, the Group achieved revenue of approximately HK$14.96 billion (2024: approximately HK$9.50 billion), representing a year-on-year increase of approximately 57.6%. Impacted by factors such as a decline in the average selling price of crude oil and coal, and higher raw material costs, profit attributable to ordinary shareholders of the Company amounted to approximately HK$0.17 billion (2024: HK$0.57 billion). Despite that, all of the Group’s segments recorded profits for the Year and the Group continued to maintain a strong financial position with cash and deposits of approximately HK$3.52 billion as at 31 December 2025 (31 December 2024: HK$2.03 billion). As at 31 December 2025, the Group had total assets of approximately HK$14.61 billion, and net assets attributable to ordinary shareholders of the Company of approximately HK$8.79 billion. The gearing ratio and interest-bearing debt ratio were approximately 38.8% and 23.5% respectively, with a return on equity (annualised) of approximately 2.0%.As part of its efforts to optimise its asset structure, the Group disposed of shares in Alcoa in January and March 2026, totalling approximately 2.17% of Alcoa’s total issued shares[1]. By seizing the opportunity to monetise its investment at a high valuation, the Group continues to create greater value for its shareholders.Mr. Hao Weibao, Executive Director, Chairman and Chief Executive Officer of CITIC Resources, said: “Looking ahead to 2026, the Group will focus on key areas such as the development, production and trading of oil and gas, as well as investments in the aluminum industry chain, deepen synergies among trading, investment and production management, and continue to implement the business strategy of consolidating the existing core business and pursuing dual-engine expansion through ‘investment + trading’.To consolidate our existing principal business, the Group will continue to enhance lean production and operational management to increase reserves and output, while steadily expanding production and sales scale. The Group will also intensify the introduction and application of new processes and technologies, leveraging technological innovation to empower high-quality development of our core businesses and reinforce our core growth foundation.On the dual-engine driver of ‘investment + trading’ expansion front, the Group will continue to track and position in high-quality oil and gas assets and the aluminium-centric key metals industry chain. Trading operations and investment projects will be deeply integrated: the investment arm will secure equity resources, while the trading arm will achieve market-oriented sales. This approach will also enhance our market sensitivity, enabling us to identify and acquire high-quality upstream resources and assets, thereby creating a virtuous cycle in which ‘investment acquires resources and trading converts value’. The Group is committed to implementing these development strategies and will continue to deliver long-term and stable returns to our shareholders.”[1]Details regarding the disposal were disclosed in the announcements and circular dated 16 January, 6 February, and 5 March.For details of CITIC Resources’ 2025 annual results, please refer to the Group’s annual results announcement on the Hong Kong Stock Exchange and the Group’s website.About CITIC Resources Holdings Limited (Stock Code: 1205.HK)CITIC Resources Holdings Limited has been listed on the Hong Kong Stock Exchange since 1997. Principal activities of CITIC Resources include the exploration, development and production of oil and coal, investments in bauxite mining, alumina refinery, aluminium smelting and oil and gas trading. CITIC Limited is the largest shareholder with about 59.5% interest in CITIC Resources. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

中信資源深化「投資+貿易」雙輪戰略 持續驅動高質量發展 推進「上游資產布局、貿易業務拓展、生產運營提質」

acn

香港, 2026年3月13日 - (亞太商訊 via SeaPRwire.com) - 中信資源控股有限公司（「中信資源」或「公司」，連同其附屬公司統稱為「集團」；股份代號：1205.HK）公布截至2025年12月31日止年度（「年内」）之全年業績。年內集團積極應對複雜國際市場環境及行業週期性波動壓力，系統推進「上游資產布局、貿易業務拓展、生產運營提質」工作，深化「投資+貿易」雙輪驅動發展模式，穩固經營基本盤，培育第二增長曲線，彰顯了強大的經營和發展韌性。作為集團主要的增長引擎之一，進出口業務板塊中的油氣貿易業務年內穩步拓展，貿易量超2,000萬桶，實現貿易收入約113.4億港元，達成重大里程碑。集團同時打破權益油銷售多年被壟斷局面，提升權益油市場價值。非油業務方面，集團始終將參股項目的精細化、主動化管理作為核心工作，向作業方傳導提質增效理念，其中所持有的美國鋁業公司（「美國鋁業」）股份價值年內增長46.3%。油氣業務方面，集團以精細化油藏管理與持續科研攻關為核心，實現穩產增儲；全面深化生產過程的精益管理，落實降本增效舉措，推動油氣項目在勘探、開發及生產各環節的管理水平和運營效益持續提升。年內，集團實現營業收入約149.6億港元（2024年：約95.0億港元），同比增長約57.6%。受原油及煤炭的平均售價下降、原材料成本上升等因素影響，本公司普通股股東應佔溢利約1.7億港元（2024年：約5.7億港元）。儘管如此，集團全部分類於本年度錄得溢利，且於2025年12月31日繼續維持穩健的財務狀況，現金及存款約為35.2億港元（2024年12月31日：20.3億港元）。截至2025年12月31日，集團總資產146.1億港元，歸母淨資產約87.9億港元，資產負債率約38.8%，有息負債率約23.5%，淨資產收益率約2.0%。作為優化資產結構的舉措之一，集團於2026年1月及3月先後減持美國鋁業股份，累計出售相當於其已發行股份總數約2.17%。集團精準把握高位變現的時機，持續為股東創造更大價值[1]。中信資源執行董事、主席兼行政總裁郝維寶先生表示：「展望2026年，集團將聚焦油氣開發生產與貿易、鋁產業鏈投資等關鍵領域，深化貿易、投資與生產運營協同，持續貫徹『夯實存量主業、「投資+貿易」雙輪拓展』的經營策略。夯實存量主業方面，集團將持續深化精益生產運營管理，實現增儲上產，穩步擴大產銷規模；同時加大新工藝、新技術引進與應用力度，以科技創新賦能主業高質量發展，築牢核心發展根基；『投資+貿易』雙輪拓展方面，持續跟蹤和佈局優質油氣資產及以鋁為核心的關鍵金屬產業鏈，貿易業務與投資項目形成深度聯動，投資端獲取權益資源，貿易端實現市場化銷售，同時形成市場觸角，識別並獲取位於產業鏈上游的優質資源資產，形成『投資獲取資源，貿易轉化價值』的良性循環。集團將致力落實此等發展戰略，持續為廣大股東創造長期穩定的價值回報。」[1]出售事項的相關詳情可見於1月16日、2月6日及3月5日刊出的公告及通函。有關中信資源2025年全年業績的詳情，請參考集團在香港聯交所及其網站的全年業績公告。關於中信資源控股有限公司（股份代號：1205.HK）中信資源控股有限公司自1997年起，在香港聯合交易所上市。中信資源的主要業務包括石油和煤的勘探、開發和生產，於鋁土礦開採、氧化鋁冶煉和電解鋁領域的投資及油氣貿易。中國中信股份有限公司持有中信資源約59.5%的股權，為中信資源最大股東。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

康哲藥業：腎性貧血新藥德昔度司他片中國獲批上市

acn

深圳, 2026年3月13日 - (亞太商訊 via SeaPRwire.com) - 康哲藥業控股有限公司(867.HK/8A8.SG)（「康哲藥業」）欣然宣佈，腎性貧血新藥德昔度司他片（原名：德度司他片）（「產品」）上市許可申請已於2026年3月13日獲得中國國家藥品監督管理局（NMPA）批准。產品為一種創新型口服低氧誘導因子-脯氨醯羥化酶抑制劑（HIF-PHI），適用於非透析的成人慢性腎臟病（CKD）患者的貧血治療。德昔度司他片獲批上市，將進一步強化康哲藥業在腎病專科領域的整體佈局，並與處於商業化階段的創新藥維福瑞（蔗糖羥基氧化鐵咀嚼片，用於CKD高磷血症）協同增效。通過腎內科專家資源與渠道網絡的高效聯動，康哲藥業有望快速推動德昔度司他片的規模化臨床應用，為中國CKD腎性貧血患者提供差異化的治療選擇，為集團業績帶來積極貢獻。關於德昔度司他片和腎性貧血的更多信息作為一種創新型口服HIF-PHI，產品作用機制為通過增加內源性促紅細胞生成素的生成、改善鐵的利用率和降低鐵調素的水平來促進紅細胞生成。其中國III期臨床試驗取得了積極結果。主要研究終點血紅蛋白（Hb）水平（第7-9周Hb平均值相對於基線的變化）結果顯示，試驗組優於安慰劑組。擴展期研究結果顯示，產品可使Hb水平長期維持在達標水平，且安全性良好。此外，產品還可以顯著降低鐵調素水平，糾正鐵代謝紊亂。中國CKD貧血治療領域仍存在顯著的未被滿足需求。據估計，中國有超過1.2億CKD患者[1]，貧血作為其常見併發症之一，發生率隨病程進展呈逐步升高趨勢。國內一項調研顯示，CKD1～5 期患者貧血患病率依次為：22.0%、37.0%、45.4%、85.1%和98.2%[2]。血液透析CKD貧血患者的治療達標率（Hb水平達到靶目標值（110～120 g/L））已提升至51.5%[3]，但對於非透析CKD貧血患者來說仍僅為8.2%[4]。產品採用口服給藥，有望提高患者的治療順應性，有望滿足CKD貧血領域未被滿足的治療需求。產品已在印度獲批上市。康哲藥業之全資附屬公司康哲國際發展管理有限公司通過生效日為2020年1月20日的《許可協議》從Zydus Lifesciences Limited（前稱為Cadila Healthcare Limited）處獲得產品的獨家許可權利。康哲藥業堅持 「創新驅動」 核心戰略，已構建起梯隊銜接、儲備充足的立體化創新產品矩陣：7款新藥獲批上市、6款正處於上市審評階段、近20個項目即將開展/正在推進臨床試驗。康哲藥業通過「合作開發+自主研發」雙輪驅動創新，持續豐富以全球首創（FIC）、同類最優（BIC）產品為核心的創新管線，高效推進臨床開發與商業化落地。未來，康哲藥業將繼續以臨床需求為導向，提供更多優質醫藥解決方案，堅定向專科聚焦、創新卓越的國際化醫藥企業邁進。關於康哲藥業康哲藥業是一家鏈接醫藥創新與商業化，把控產品全生命週期管理的開放式平臺型企業，致力於提供有競爭力的產品和服務，滿足尚未滿足的醫療需求。康哲藥業專注於全球首創（FIC）及同類最優（BIC）的創新產品，並高效推進創新產品臨床研究開發和商業化進程，賦能科研成果向診療實踐的持續轉化，造福患者。康哲藥業聚焦專科領域，擁有被驗證的商業化能力，廣泛的渠道覆蓋和多疾病領域專家資源，核心在售產品已獲領先的學術與市場地位。康哲藥業圍繞優勢專科領域不斷縱深發展，以鞏固心腎代謝/消化/眼科/皮膚健康業務競爭力，帶來專科規模效率，其中皮膚健康業務（德鎂醫藥）已成為其細分領域的龍頭企業，並擬於聯交所獨立上市。同時，康哲藥業持續推動研產銷全產業鏈在東南亞及中東區域運營發展，以獲取新興市場的增量，助力集團實現高質量可持續發展。參考文獻/資料1.ZhangL, WangF, WangL, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey[J]. Lancet, 2012, 379(9818):815-822. DOI: 10.1016/S0140-6736(12)60033-62.腎性貧血診斷與治療中國專家共識（2014修訂版）[J]. 中華腎臟病雜誌, 2014, 30(9): 712-716. DOI: 10.3760/cma.j.issn.1001-7097.2014.09.0153.中華醫學會腎臟病學分會第十九屆重症腎臟病與血液淨化大會（2025年7月2-5日）4.腎性貧血診斷與治療中國專家共識（2018修訂版）[J]. 中華腎臟病雜誌, 2018, 34(11): 860-866. DOI: 10.3760/cma.j.issn.1001-7097.2018.11.012康哲藥業免責與前瞻性聲明本新聞無意向您做任何產品的推廣，非廣告用途。本新聞不對任何藥品和醫療器械和/或適應症作推薦。若您想瞭解具體疾病診療信息，請遵從醫生或其他醫療衛生專業人士的意見或指導。醫療衛生專業人士作出的任何與治療有關的決定應根據患者的具體情況並遵照藥品說明書。由康哲藥業編制的此新聞不構成購買或認購任何證券的任何要約或邀請，不形成任何合約或任何其他約束性承諾的依據或加以依賴。本新聞由康哲藥業根據其認為可靠之資料及數據編制，但康哲藥業並無進行任何說明或保證、明述或暗示，或其他表述，對本新聞內容的真實性、準確性、完整性、公平性及合理性不應加以依賴。本新聞中討論的若干事宜可能包含涉及康哲藥業的市場機會及業務前景的陳述，該等陳述分別或統稱為前瞻性聲明。該等前瞻性聲明並非對未來表現的保證，存在已知及未知的風險、不明朗性及難以預知的假設。康哲藥業並不採納本新聞包含的第三方所做的任何前瞻性聲明及預測，康哲藥業對該等第三方聲明及預測不承擔責任。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

uSMART HK Expands to 12 Physical Service Centres in One Year, Accelerating “Online x Offline” O2O Community Finance Strategy

acn

HONG KONG, Mar 13, 2026 - (ACN Newswire via SeaPRwire.com) – uSmart Securities Limited ("uSMART Securities/the Company") is pleased to announce the official opening of its ninth and tenth physical service centres in Tai Wai and Tuen Mun. Within just one year, uSMART Securities has expanded its Hong Kong service network to 12 physical service centres, surpassing industry benchmarks and actively implementing its "Online x Offline" (O2O) community finance strategy. This expansion solidifies its position as the “No.1 Hong Kong Funded Fintech Brokerage^” and further enhances brand influence.Promoting Accessible Community Financial ServicesThe Tuen Mun branch held a simple yet meaningful opening ceremony today, marking the official commencement of services and a new chapter in the Company's development. Mr. Neo Lee, Executive Director of uSMART Securities, stated: "The opening of the Tai Wai and Tuen Mun branches represent a crucial strategic move in our commitment to local communities and advancing community-oriented services. We focus not only on network coverage but also on connecting with the community, upholding our 'customer-centric' philosophy. By bridging the gap with residents, we are advancing toward our goal of 'seamless coverage across Hong Kong'."(From left to right: Business Development Manager of uSMART Securities, Executive Director of Research Department of uSMART Securities, Executive Director of uSMART Securities, Marketing Director of uSMART Securities and Business Development Director of uSMART Securities)(From left to right: Business Development Manager of uSMART Securities, Executive Director of Research Department of uSMART Securities, Executive Director of uSMART Securities, Marketing Director of uSMART Securities and Business Development Director of uSMART Securities)Comprehensive Coverage Across Hong Kong 18 DistrictsAiming to accelerate the goal of becoming "the Fintech brokerage with the most service centres in Hong Kong," uSMART Securities will open branches in core areas, Kai Tak and Mong Kok in the second quarter. The company is also actively exploring pop-up stores in shopping malls and participating in various exhibition booths. Through multi-channel engagement with customers across different districts, the company aims to refine its regional presence, enabling citizens across all 18 districts to easily access professional and personalized investment and wealth management services, seamlessly integrating financial experiences into daily life.Diversified Investment ProductsAt the opening ceremony, Neo revealed that uSMART Securities has recently obtained a futures trading license and is preparing to launch futures trading services by mid-year. Upon launch, clients will be able to trade futures, including index futures, commodity futures, and currency futures via the uSMART platform. This expansion provides investors with a more comprehensive range of investment products covering long-term, medium-term, and short-term investments, as well as low, medium, and high expected returns, catering to diverse client needs.Futures services will be fully integrated into the existing uSMART APP trading platform, allowing clients to trade US and Hong Kong stocks, futures, ETFs, funds, and discretionary investment products from a single APP. This enables diversified asset allocation, risk management, and wealth enhancement services, allowing clients to utilize capital efficiently and manage investment portfolios flexibly, truly achieving "one-stop wealth management with comprehensive asset allocation."Promoting Investment Education and Enhancing Client InteractionuSMART Securities is also committed to advancing investor education, regularly hosting various online and offline investment seminars and thematic events such as wine tastings and cocktail workshops. These initiatives deepen client engagement and relationships, enhancing customer retention and loyalty.Meanwhile, a new financial channel led by stock commentator and Executive Director of Research, Mr. Dickie Wong, will officially launch next Monday (March 16). Before the market opens and midday close on every Hong Kong stock trading day, a professional team will provide you with real-time analysis of market dynamics and investment opportunity. uSMART Securities aims to foster closer interaction, helping clients refine their practical skills, optimize investment decisions, and build a more comprehensive platform for learning and practice.Expanding Team SizeIn line with rapid business growth, uSMART Securities is actively advancing local talent recruitment and training. The company expects to increase its workforce by 30% over the next two years across areas including branch operations, product design, wealth management, compliance and risk control, and marketing operations. This expansion aims to enhance team scale and professional capabilities, driving steady business growth.Looking ahead, uSMART Securities will continue to optimize trading experiences and strengthen synergies between offline service points and community activities, further solidifying its leading position in financial technology. By combining innovative technology with community networks, the company strives to provide more convenient and personalized wealth management services for investors of all ages and experience levels, promoting the popularization and intelligent development of Hong Kong's financial ecosystem.^”No.1 Hong Kong Funded Fintech Brokerage" is based on TradeGo Cloud data, with uSMART Securities ranking first in monthly transaction volume among local Hong Kong-funded internet brokers for over a year as of February 2026.About uSMART:uSMART Securities is a leading Hong Kong Funded Fintech Brokerage founded in 2018. Over the past eight years, it has pioneered the fusion of technology and finance, offering stocks trading, asset management, and wealth management solutions. Its proprietary platforms, uSMART HK APP and uSMART SG APP, operated by uSMART Securities (Hong Kong) and uSMART Securities (Singapore) respectively. It supports investments in Hong Kong stocks, US stocks, A-shares (via Shanghai and Shenzhen Stock Connect), Singapore Stocks, Japan Stocks, UK Stocks, US options, ETFs, Funds, Bonds, Asset Management, Structured Notes, Futures, Crypto, Precious Metals, Gold, and forex. Furthermore, uSMART is equipped with a highly professional research and asset management team that offers asset management, wealth management, securities brokerage, institutional business, LPF services, and investment banking, dedicated to serving ultra-high-net-worth individuals and families, corporations, investment institutions, fund companies, and other brokerage firms with comprehensive asset management solutions.For details please visit: https://hk.usmartglobal.comFor any media queries, please contact:Carrie Wong9788 4665carriewong@usmart.hk Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

盈立證券一年拓展12個服務網點 全力深化「線上x線下」O2O社區金融佈局

acn

香港, 2026年3月13日 - (亞太商訊 via SeaPRwire.com) - uSMART盈立證券有限公司（下稱「盈立證券」或「本公司」）欣然宣佈，第九及第十間實體服務中心正式進駐大圍及屯門，短短一年內，盈立證券全港服務網絡已增至12間服務中心，超越全行，積極實踐「線上 x 線下」（O2O）社區金融策略，鞏固港資科技券商No.1^地位，進一步擴大品牌影響力。推動社區金融服務普及化屯門分行今日舉行簡單而隆重的開幕典禮，標誌該分行正式投入服務，為本公司的發展里程寫下嶄新一頁。盈立證券執行董事李建翰先生 (Neo) 表示：「大圍及屯門分行的開業，是我們心繫本地社區，持續推動社區化服務的重要戰略性部署。我們不僅追求網絡覆蓋率，更重視與社區的連結，貫徹『以客為本』的理念，拉近與居民的距離，朝『全港無縫覆蓋』的目標邁進。」(左起︰盈立證券業務拓展經理林向尊先生、盈立證券研究部執行董事黃德几先生、盈立證券執行董事兼機構業務負責人李建翰先生、盈立證券香港市場部總監黃曉霖小姐及盈立證券業務拓展總監鄧永麟先生)(左起︰盈立證券業務拓展經理林向尊先生、盈立證券研究部執行董事黃德几先生、盈立證券執行董事兼機構業務負責人李建翰先生、盈立證券香港市場部總監黃曉霖小姐及盈立證券業務拓展總監鄧永麟先生)全港18區服務全覆蓋為加速實現『全港最多服務中心的科技券商』的目標，盈立證券將於第二季在核心地區 ─ 啟德及旺角開設分行，並積極物色商場期間限定店及參與各類展會攤位，希望透過多渠道接觸不同地區客戶，藉此進一步完善地區性佈置，讓全港18區市民皆可輕鬆獲取專業、個性化的投資理財服務，把金融體驗融入日常生活。」投資產品多元化Neo在開幕典禮上透露，盈立證券早前更取得期貨交易牌照，並正籌備於年中正式推出相關期貨交易業務。屆時客戶可透過uSMART平台進行期貨交易，涵蓋指數期貨、商品期貨及外匯期貨等，為投資者提供更全面的投資產品，長、中、短線投資以及低、中、高預期回報俱備，滿足不同客戶的需求。期貨業務將全面整合至現有的 uSMART APP交易平台，客戶可使用同一個APP買賣美港股、期貨、ETF、基金及全權委託投資產品等，即可享受多元資產配置、風險管理及財富增值服務，高效地運用資金，靈活地管理投資組合，真正實現「一站式理財．全方位佈局」。推動投資教育 強化客戶互動體驗盈立證券對推動投資者教育亦不遺餘力，定期舉辦不同類型的線上及線下的投資講座，及主題活動，如葡萄酒品鑑會及雞尾酒工作坊，深化與客戶的互動與關係，提升客戶黏度，增加客戶忠誠度。同時，由資深股評人兼研究部執行董事黃德几先生（Dickie）親自帶領的全新財經台，將於下周一（3月16日）強勢啟播，每個港股交易日的早上開市及中午收市前，由專業團隊為您即時剖析市場動態與投資機遇。盈立證券期望透過更緊密的互動，協助客戶精進實戰技巧、優化投資決策，打造更完善的學習與實踐平台。擴大團隊規模　配合業務高速發展，盈立證券正積極推進本地人才招募與培訓，預計未來兩年職位數量將增加30%，涵蓋前線分行、產品設計、財富管理、合規風控及市場營運等範疇，全面擴大團隊的規模及專業能力，推動業務穩健成長。 展望未來，盈立證券將持續優化交易體驗，並加強線下網點與社區活動的協同效應，進一步鞏固在金融科技領域的領先地位；同時結合創新科技與社區網絡，為不同年齡及資歷的投資者提供更便捷、更具溫度的理財服務，推動本地金融生態朝普及化及智能化發展。^「港資科技券商No.1」是取自捷利金融雲截至2026年2月為止連續超過一年數據， uSMART盈立證券為香港本地港資互聯網券商月成交總額排行第1。關於uSMART盈立證券：盈立證券 是一間領先科技港資券商，成立於2018年，8年來憑藉卓越的戰略規劃和創新能力，致力於將科技與金融深度融合，業務範圍涵蓋證券、資產管理、財富管理等領域，為全球投資者獨家研發了金融證券交易平台 uSMART HK APP和 uSMART SG APP，分別由盈立證券（香港）和盈立證券（新加坡）提供服務。集團APP 支持港股、美股、A股（滬深港通）、新加坡股票、日本股票、英國股票、美股期權、ETF、基金、債券、資管、結構化票據、期貨、加密貨幣、貴金屬、黃金和外匯等多元化的投資交易服務，此外更為超高淨值個人與家族、企業提供度身訂制服務，打造全方位綜合性資產管理解決方案。詳情可瀏覽 https://hk.usmartglobal.com傳媒查詢：黃曉霖 Carrie Wong9788 4665carriewong@usmart.hk Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

CMS (867.HK/8A8.SG): Ruxolitinib Phosphate Cream (Lumirix(R)) Achieves Initial Prescriptions in Multiple Regions in China for Patients with Vitiligo

acn

SHENZHEN, CHINA, Mar 13, 2026 - (ACN Newswire via SeaPRwire.com) - On 12 March 2026, China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health, which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited) has its innovative prescription medicine ruxolitinib phosphate cream (Lumirix®) (the “Product”, marketed as Opzelura® in the U.S., Europe and Canada) recorded the initial prescriptions for vitiligo patients across 30 provincial-level regions. The prescriptions cover approximately a thousand influential public and private medical institutions in the field of skin health and disease management, including Huashan Hospital, Fudan University, Shanghai Skin Disease Hospital, Dermatology Hospital of Southern Medical University, Second People's Hospital of Chengdu, The First Bethune Hospital of Jilin University, The Second Xiangya Hospital of Central South University, United Family Healthcare Group, among others*. Meanwhile, the Product has become concurrently accessible via over 1,300 offline drugstores as well as JD.com e-commerce platform. *Hospital rankings are listed in no particular order.As the first topical JAK inhibitor approved in China for the treatment of vitiligo, ruxolitinib phosphate cream has officially launched its large-scale clinical application today, marking a breakthrough in China’s vitiligo treatment landscape and ushering in a new era of precision targeted therapy for vitiligo. Supported by safety and efficacy fully demonstrated in clinical studies, the Product is expected to bring new hope for repigmentation to millions of vitiligo patients.The rapid commercialization progress of ruxolitinib phosphate cream underscores strong product operation capabilities of CMS (including Dermavon), while also reflecting the robust supports from China’s regulatory reforms in accelerating patient access to clinically urgently needed innovative drugs. Benefiting from the integrated healthcare ecosystem of the Hainan Free Trade Port and the “Urgently Needed Imported Drugs for Clinical Use” policy, the Product initiated pilot clinical use in August 2023 at Boao Super Hospital within the Boao Lecheng International Medical Tourism Pilot Zone. Pilot usage subsequently expanded to designated medical institutions across the Guangdong–Hong Kong–Macao Greater Bay Area, Beijing-Tianjin region and other regions. In accordance with the relevant regulations of China’s real-world data application pilot project, as well as supported by the Hainan Provincial Medical Products Administration and the Administration of the Boao Lecheng International Medical Tourism Pilot Zone, the Product has accumulated real-world clinical data in China under pilot application, significantly accelerating its clinical, registration and approval timelines. The Product received its Drug Registration Certificate on January 30, 2026 (approval date: January 27, 2026).Following its approval, in less than 1.5 months (including the Chinese New Year holiday), the initial prescriptions for ruxolitinib phosphate cream have been issued across multiple regions and hospitals, reflecting the highly efficient collaboration and concerted efforts among CMS teams, regulatory authorities and business partners. With robust support from the cross-departmental coordination mechanism of the Beijing Daxing Airport Economic Zone Joint Administrative Committee, once import conditions were met, the Product completed customs clearance approval, sampling and related customs procedures within 24 hours, and obtained the drug testing report within 7 working days, representing efficient execution and acceleration for the innovative drugs in China. During this process, the Beijing Municipal Medical Products Administration proactively provided end-to-end policy guidance; the government service center has efficiently completed customs clearance filing; the Beijing Institute for Drug Control has conducted methodological pre-testing to accelerate timelines for innovative drug, and continuous worked during the Chinese Spring Festival; and Daxing Airport Customs provided specialized pre-guidance on declaration and swiftly completed customs review and release. Through parallel workflows and coordinated execution, all parties collectively pressed the “fast-forward button” for the Product’s commercialization, helping this urgently needed innovative therapy reach patients faster.As the Product enters the large-scale clinical application stage, it is expected to further strengthen Dermavon’s comprehensive dermatology solutions and brand value. Building on its leadership in skin health, Dermavon will continue to improve accessibility of ruxolitinib phosphate cream to benefit more vitiligo patients and steadfastly safeguard public skin health through innovation.About VitiligoVitiligo is a chronic autoimmune disease characterized by depigmentation of the skin, which results from the loss of pigment-producing cells known as melanocytes. The discolored areas usually get bigger with time and the condition could influence skin on any part of the patients’ body. Vitiligo usually affects the appearance of patients, especially on exposed areas such as the face and neck. According to a study that involved over 1,000 diagnosed vitiligo patients, over 45% of patients have facial involvement, and over 20% of patients have neck involvement[1].The obvious presence of white patches may make patients feel that their appearance has been compromised, which in turn materially affects their social life, and is associated with a significantly higher incidence of mental health disorders; accordingly, there is an urgent need for effective treatment options for vitiligo[2].It is estimated that there are approximately 10.3 million vitiligo patients in China and non-segmental vitiligo patients account for approximately 8.2 million[1]. Existing therapies, such as topical corticosteroids (TCS) and topical calcineurin inhibitors (TCIs), have clinical limitations, with adverse reactions or limited efficacy with long-term use. Ruxolitinib phosphate cream successfully fills the gap in targeted drug treatment for vitiligo and is of great landmark significance.More Information About Ruxolitinib Phosphate CreamRuxolitinib phosphate cream (Opzelura®), a novel cream formulation of the selective JAK1/JAK2 inhibitor ruxolitinib developed by Incyte, is the first and only drug approved for the repigmentation of non-segmental vitiligo by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA)[3,4]. In the U.S., the Product is indicated for the topical treatment of nonsegmental vitiligo in adult and pediatric patients aged 12 years and older, and for the short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis (AD) in non-immunocompromised adult and pediatric patients aged 2 years and older whose disease is not well controlled with topical prescription therapies, or when those therapies are not advisable. In Europe, ruxolitinib phosphate cream is approved for the topical treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age. In China, besides vitiligo indication, the product’s NDA for the treatment of mild-to-moderate AD in adults and pediatric patients aged 2 years and older is also under regulatory review, which has been included in the Priority Review List and is expected to accelerate the Product’s AD review process for marketing approval.The Group, through the subsidiary of Dermavon entered into a Collaboration and License Agreement with Incyte for ruxolitinib phosphate cream on 2 December 2022, obtaining an exclusive license to develop, register and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in the Territory. The subsidiary of Dermavon has sublicensed the relevant rights for the Product outside of Mainland China to the Group (excluding Dermavon and its subsidiary).Incyte has worldwide rights for the development and commercialization of ruxolitinib phosphate cream (excluding territories in which exclusive rights have already been licensed), marketed in the United States and Europe as Opzelura®. Opzelura® and the Opzelura® logo are registered trademarks of Incyte.About CMSCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardiovascular-kidney-metabolic/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group.Reference:1. China Insights Consultancy’s industrial report 2. Wang G, Qiu D, Yang H, Liu W. The prevalence and odds of depression in patients with vitiligo: a meta-analysis[J]. Journal of the European Academy of Dermatology and Venereology, 2018,32(8):1343-1351. DOI:10.1111/jdv.14739. 3. The U.S. FDA approval information can be found on the Incyte official website, as follows:https://investor.incyte.com/news-releases/news-release-details/incyte-announces-us-fda-approval-opzeluratm-ruxolitinib-cream4. The EMA approval information can be found on the Incyte official website, as follows:https://investor.incyte.com/news-releases/news-release-details/incyte-announces-european-commission-approval-opzelurarCMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsWebsite: https://web.cms.net.cn/en/home/ Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com